General Hospital Psychiatry
Volume 29, Issue 5 , Pages 446-449 , September 2007

Long-term topiramate treatment of psychotropic drug-induced weight gain: a retrospective chart review

  • Yasser Khazaal, M.D.

      Affiliations

    • Department of Psychiatry, University Hospital of Vaud, CH-1004 Lausanne, Switzerland
    • Corresponding Author InformationCorresponding author.
    • ,
  • Anne Chatton, M.A.

      Affiliations

    • Division of Substance Abuse, University Hospitals of Geneva, 1205 Geneva, Switzerland
    • ,
  • Manon Rusca, B.A.

      Affiliations

    • Department of Psychiatry, University Hospital of Vaud, CH-1004 Lausanne, Switzerland
    • ,
  • Martin Preisig, M.D.

      Affiliations

    • Department of Psychiatry, University Hospital of Vaud, CH-1004 Lausanne, Switzerland
    • ,
  • Daniele Zullino, M.D.

      Affiliations

    • Division of Substance Abuse, University Hospitals of Geneva, 1205 Geneva, Switzerland

Received 28 February 2007 ,Accepted 9 May 2007.

References 

  1. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003;28(Suppl 1):83–96
  2. Green AI, Patel JK, Goisman RM, et al. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry. 2000;22(4):224–235
  3. Chengappa KN, Chalasani L, Brar JS, et al. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clin Ther. 2002;24(10):1576–1584
  4. Brar JS, Ganguli R, Pandina G, et al. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005;66(2):205–212
  5. Khazaal Y, Fresard E, Rabia S, et al. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr Res. 2007;91(1–3):169–177
  6. Werneke U, Taylor D, Sanders TA. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol. 2002;17(4):145–160
  7. White HS, Brown SD, Woodhead JH, et al. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 1997;28(3):167–179
  8. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11(6):722–733
  9. Wilding J, Van Gaal L, Rissanen A, et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord. 2004;28(11):1399–1410
  10. Astrup A, Caterson I, Zelissen P, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res. 2004;12(10):1658–1669
  11. Tremblay A, Chaput JP, Berube-Parent S, et al. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur J Clin Pharmacol. 2007;63(2):123–134
  12. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532–546
  13. Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res. 2006;82(1):115–117
  14. Gupta S, Masand PS, Frank BL, et al. Topiramate in bipolar and schizoaffective disorders: weight loss and efficacy. Prim Care companion J Clin Psychiat. 2000;2(3):96–100
  15. Erfurth A, Kuhn G. Topiramate monotherapy in the maintenance treatment of bipolar I disorder: effects on mood, weight and serum lipids. Neuropsychobiology. 2000;42(Suppl 1):50–51
  16. Lin YH, Liu CY, Hsiao MC. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin Neurosci. 2005;59(5):613–615
  17. Nickel MK, Nickel C, Muehlbacher M, et al. Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005;25(3):211–217
  18. Ko YH, Joe SH, Jung IK, et al. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol. 2005;28(4):169–175
  19. Kirov G, Tredget J. Add-on topiramate reduces weight in overweight patients with affective disorders: a clinical case series. BMC Psychiatry. 2005;5(1):19
  20. Vieta E, Goikolea JM, Olivares JM, et al. 1-Year follow-up of patients treated with risperidone and topiramate for a manic episode. J Clin Psychiatry. 2003;64(7):834–839
  21. McElroy SL, Shapira NA, Arnold LM, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry. 2004;65(11):1463–1469
  22. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(2):255–261
  23. McElroy SL, Hudson JI, Capece JA, et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 2007;61(9):1039–1048
  24. Biton V, Edwards KR, Montouris GD, et al. Topiramate titration and tolerability. Ann Pharmacother. 2001;35(2):173–179
  25. Fedoroff I, Polivy J, Herman CP. The specificity of restrained versus unrestrained eaters' responses to food cues: general desire to eat or craving for the cued food?. Appetite. 2003;41(1):7–13
  26. Zullino DF, Krenz S, Zimmerman G, et al. Topiramate in opiate withdrawal — comparison with clonidine and with carbamazepine/mianserin. Subst Abus. 2005;25(4):27–33
  27. Fallon AE, Rozin P. Sex differences in perceptions of desirable body shape. J Abnorm Psychol. 1985;94(1):102–105
  28. Khazaal Y, Fresard E, Zimmermann G, et al. Eating and weight related cognitions in people with schizophrenia: a case control study. Clin Pract Epidemol Ment Health. 2006;2:29

PII: S0163-8343(07)00095-3

doi: 10.1016/j.genhosppsych.2007.05.001

General Hospital Psychiatry
Volume 29, Issue 5 , Pages 446-449 , September 2007

Article Tools

* Image Usage & Resolution